Wednesday, September 7, 2011

Prostate Update

Biopsy
Needle biopsies that follow an abnormally high PSA reading are increasingly resulting in infection by antibiotic-resistant strains of bacteria such as E. coli. Research shows that the risk of post-biopsy infection - while still small - has more than doubled in less than a d

Diet

Coffee contains many biologically active compounds, including caffeine and phenolic acids, that have potent antioxidant activity and can affect glucose metabolism and sex hormone levels. Because of these biological activities, coffee may be associated with a reduced risk of prostate cancer. Of 47,911 men in the Health Professionals Study, a strong inverse association between coffee consumption and risk of lethal prostate cancer. The association appears to be related to non-caffeine components of coffee. Journal of the National Cancer Institute. September 2011
Environment
An American Journal of Epidemiology study provides evidence of an association between prostate cancer and ambient pesticide exposures in and around homes in intensely agricultural areas. The associations appear specific to compounds with a plausible biologic role in prostate carcinogenesis.


EstrogenIn vivo and in vitro studies have identified multiple mechanisms of potential carcinogenesis, including direct genotoxicity, epigenotoxicity, hyperproloctinemia, chronic inflammation and prostatic ER-mediated changes that are in addition subject to disruption by environmental estrogens. Moreover, ample evidence for estrogen's role in the development of human prostate cancer exists in the form of epidemiological data and associations between inflammation and cancer. According to commentary in Expert Review of Endocrinology and Metabolism. The true role of estrogen in prostate cancer development and progression is probably complex and multifactorial, incorporating more than one of the mechanisms already described and with interplay between them. Although circulating estrogen levels may not correlate well with intraprostatic levels, particularly in light of recent evidence of intraprostatic estrogen production, serum values offer an easily accessible surrogate marker to investigate associations between estrogen and prostate cancer risk.

Other Cancers From Prostate Therapy
Men treated with hormone-based therapy for prostate cancer faced a 30 percent to 40 percent higher risk of colorectal cancer, compared to patients who did not receive this treatment. This study looked at use of androgen deprivation therapy, a common type of treatment for prostate cancer that involves blocking the male hormone testosterone through either surgical removal of the testicles or a series of injections.
Patients who had their testicles removed, a procedure called orchiectomy, had the highest rates of colorectal cancer. Researchers looked at data from 107,859 men aged 67 and older with prostate cancer. Results of the study were published online in the Journal of the National Cancer Institute.

Pharmaceuticals
The FDA recently approved Provenge (autologous cellular immunotherapy)
designed to use your immune system to fight prostate cancer. It is the first medication with this action to be approved. While promising, we still say give it the two-year rule before trying unless cancer is advanced.

The FDA has issued a warning of an increased risk of high-grade prostate cancer with the 5-alpha reductase inhibitors finasteride (Proscar) and dutasteride (Avodart) currently approved to treat benign prostatic hypertrophy. The agency announced that it has updated the Warnings and Precautions section of labels for the class of drugs -- which includes branded products Propecia and Jalyn under which finasteride and dutasteride are marketed for other indications -- to reflect the increased risk. Avodart, Jalyn, and Proscar are approved to treat symptoms of an enlarged prostate. Propecia, at a 1-mg dose, is approved to treat hair loss in men. The announcement follows the FDA's Oncologic Drugs Advisory Committee vote of 17-0 in that GlaxoSmithKline's dutasteride and Merck's finasteride should not be used to prevent prostate cancer because the drugs are linked to a higher incidence of high-grade tumors.

Procedure Conundrum
Researchers claim in a study from journal Cancer Cell that when a common type of prostate cancer was treated with conventional hormone ablation therapy blocking androgen production or androgen receptor (AR) function- which drives growth of the tumor -- the cancer was able to adapt and compensate by activating a survival cell signaling pathway, effectively circumventing the roadblock put up by this treatment. The findings could have important clinical implications as this type of prostate cancer, in which the PTEN tumor suppressor gene is inactivated, accounts for about 40 to 50 percent of primary prostate cancers and 70 to 90 percent of cancers that become resistant to hormone therapy, called castration resistant prostate cancers.

Based on this study, these prostate cancers could be more effectively treated using a combination of drugs that target the AR cell signaling pathway and the compensating survival pathway. The most significant take home message from the study is that certain prostate cancers can resist androgen deprivation therapy by activating an alternate pathway to drive its growth. When we suppress one of these pathways, it essentially feeds the other.

Men who die of prostate cancer are those that become resistant to hormone ablation therapy and, as a consequence, their disease can spread or metastasize to other places, most often the bones. Clinical trials currently are being designed at that will combine these types of drugs to cut off both the primary path and escape routes that prostate cancers use to survive.

Screening Tools: Out With the Old, In With the New
A+PSA assay, a new test for prostate cancer that measures levels of prostate specific antigen (PSA) as well as six specific antibodies found in the blood of men with the disease was more sensitive and more specific than the conventional PSA test used today, according to a study from Journal of Translational Medicine. The study focused on six specific prostate-cancer associated antigens -- NY-ESO-1, SSX-2,4, XAGE-lb, AMACR, p90 and LEDGF -- which are found predominantly in patients with prostate cancer and not in benign prostate conditions. The percentage of men with prostate cancer who were correctly identified as having a malignancy -- was 79 percent compared to the 52 percent found in PSA testing.

Researchers report that nearly half of men in their seventies underwent PSA screening in the past year -- almost double the screening rate of men in their early fifties, who are more likely to benefit from early prostate cancer diagnosis and treatment. Further, men aged 85 and older were screened just as often as men in their early fifties. Because prostate cancer tends to be slow-growing, data show that many men -- particularly those in their seventies and older -- will die of other causes before prostate cancer becomes a problem that requires medical attention. Published in the Journal of Clinical Oncology, the new findings underscore a long-standing concern that overuse of PSA screening and PSA-based treatment decisions may lead to unnecessary treatment of many older men and potential complications such as incontinence, impotence and bowel dysfunction.


Related Blog Posts
Predicting Prostate Cancer With a Genetic Variation
Predicting Prostate Cancer With a Genetic Variation



The views expressed in these blog posts are those of the author and not of the Sun-Times News Group.

No comments:

Post a Comment